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1. Introduction
1.1. Aims of chapter
In this Chapter we will discuss the indications for allogeneic hematopoietic stem cell trans‐
plantation (HCT). We will focus on the appropriate timing of this procedure for the different
hematologic malignancies. We reviewed past approaches using myeloablative conditioning
and present some of the newer reduced intensity therapies. Allogeneic transplantation is one
of the first known uses of stem cells. Born from the need to rescue damaged bone marrow, it
was first used in the setting of aplastic anemia and acute leukemia. Over the years, the
technique has changed steadily and support for this procedure has improved immensely.
Today this procedure is used to treat multiple malignant blood disorders, bone marrow failure
syndromes, immune deficiency syndromes, and hemoglobinopathies. This chapter will focus
on the malignant hematopathies. Another aspect of this Chapter will be to review the condi‐
tioning regimens used in allogeneic HCT.
2. Indications for transplantation
2.1. Acute myeloid leukemia
Acute myeloid leukemia (AML) Is heterogeneous group of clonal disorders. The disease can
present at all ages, but this disorder is most commonly seen in older patients, with a median
age at presentation of 67 years. [1] AML can present in a de novo fashion or can progress from
antecedent hematological disorders, including myelodysplasia and myeloproliferative
neoplasms (secondary AML), or after prior exposure to chemotherapy and/or radiation
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therapy (treatment-related AML). Patients who are deemed fit enough to receive therapy can
be given various combinations of chemotherapy to induce a remission of the disease. The most
common induction therapy is that of cytarabine given as a continuous infusion for 7 days in
combination with an anthracycline for 3 days (the 7+3 regimen). This approach has been used
for over 40 years with very good results [2-6]. Attempts to improve on this by adding other
therapies have not resulted in improved outcomes. More recently, dose intensification of the
anthracycline has resulted in improved complete remission (CR) rates and more importantly
overall survival (OS) for patients below the age of 65 years [7-10]. Although current induction
chemotherapy regimens are successful in obtaining a CR with rates approaching 70-80%;
without consolidation chemotherapy, most patients will relapse and die of the disease. Because
of the high risk of relapse, AML is the leading indication for allogeneic transplant.
There are several significant prognostic factors that will affect the patient's ability to achieve a
CR. The most important is that of age. Other recognized factors are cytogenetic risk profile, mo‐
lecular mutations, prior exposures to chemotherapy and radiation therapy, and antecedent
hematological disorders. [11] These factors also impact on the patient's ability to maintain long-
term remission and be cured of the disease. More recently, molecular mutations have come to the
forefront in determining overall prognosis. These mutations include nucleophosmin-1 (NPM1),
fms-like tyrosine kinase-3 (FLT3), CAAT enhancer binding protein alpha (CEBPA), and c-KIT.
Retrospective analyses have shown that, in cytogenetically normal individuals, NPM-1and
CEBPA have improved survival in comparison to those with other mutations [12]. FLT3-ITD
negatively impacts all cytogenetic and molecular risk groups [12-14]. The European Leukemia
Network proposed a new prognostic designation based on both accepted cytogenetic and mo‐
lecular abnormalities [15]. More recently, newer molecular mutations have been described
which in the future may help further delineate the prognostic risk [14]. A recent retrospective
study from the Center for International Blood and Marrow Transplantation Research has also re‐
classified the cytogenetic risk for those patients proceeding to transplantation. [16]
The potential for relapse and the patient’s clinical status are factors that determine the consoli‐
dation approach. Currently, prognostic factors are used to decide on the most appropriate con‐
solidation therapy for patients with this disease. Multiple studies have demonstrated that
patients with the core binding factor AML (AML/ETO and RUNX/RUNX1] have an excellent re‐
sponse to induction and consolidation chemotherapy. [17] For these patients, allogeneic hema‐
topoietic cell transplantation (HCT) should be reserved for relapse of the disease. Contrary to
this, an unfavorable risk profile usually portends a very poor prognosis. Patients with unfavor‐
able  cytogenetics  (complex  cytogenetics,  single  or  multiple  monosomal  karyotype,  MLL
(11q23) [18]) respond very poorly to induction chemotherapy, and remissions are usually short‐
er. In patients with cytogenetically normal AML, the presence of FLT3, MLL, DNMT3A, and oth‐
ers have also demonstrated shorter disease-free survival (DFS) and OS [12, 19-21].
For more than 15 years, the standard of consolidation therapy for patients with AML in first CR
(CR1) has been intensive chemotherapy using high-dose cytarabine. However, this approach is
only effective in patients who are below the age of 60 years and have favorable risk cytogenetics
[22]. Initially, allogeneic HCT was used as salvage therapy for patients who failed conventional
chemotherapy. The sentinel paper was published by Thomas et al., who used allogeneic HCT as
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salvage therapy for 100 patients who had relapsed or refractory AML. The 13% OS gave great
hope to the use of this modality [23] Subsequent reports from the same group promoted the use
of allogeneic HCT as front-line consolidation therapy [24-27]. Randomized trials using genetic
randomization demonstrated an improved DFS in patients receiving allogeneic transplanta‐
tion [28]. Although the US Intergroup trial demonstrated there was no advantage to allogeneic
transplantation compared to intensive chemotherapy in patients with de novo AML below the
age of 60in CR1[29], more recent studies have demonstrated effectiveness of this approach. The
US Intergroup trial had a significant flaw in that a large number of patients allocated to trans‐
plantation did not receive the intended therapy. However, retrospective subset analysis did
note a significant improvement in patients with unfavorable-risk cytogenetics [30]. A meta-
analysis of five trials performed by Yanada et al. (3100 patients) demonstrated an improved OS
for patients with unfavorable-risk cytogenetic profiles. Until recently, there was no consensus
as to how to treat patients with intermediate risk AML in CR1. Meta-analyses by the HOVON-
SAKK group (925 patients) and a systematic review by Koreth et al. (6007 patients) all showed
an improved OS for patients with intermediate- and unfavorable-risk cytogenetic profiles.
These analyses were limited to related donor transplantations and to younger patients. [31-33]
A Markov analysis of 2090 Japanese patients with de novo AML in CR1 confirmed the appropri‐
ateness of a related or alternative donor HCT over chemotherapy in this setting but not for pa‐
tients  without  a  matched donor  [34].  A recent  evaluation of  patients  with  AML with  a
monosomal karyotype also demonstrated a benefit of allogeneic HCT in this group. [35] The ap‐
propriate intensity of the conditioning regimen for patients with myeloid malignancies in first
CR is currently being evaluated by the Bone Marrow Transplant Clinical Trials Network (BMT-
CTN) in a prospective randomized multi-center trial (0901).
About two-thirds of the patients with AML will not have a matched related donor (MRD). For
these patients, matched unrelated donor (MUD) transplantation is an option particularly for
those patients with unfavorable-risk profiles. A retrospective study from the CIBMTR
reviewed MRD, MUD and partial MUD transplantation in patients with unfavorable-risk
cytogenetics. Here the investigators found that MRD and MSD had similar leukemia-free
survival and OS. The benefit was not seen in partially MUD or those over the age of 50 years.
Other studies have demonstrated the similarities in outcomes compared to sibling transplants.
[36-39] The trade-off is an increase in graft versus host disease (GVHD) and its associated
mortality for increased disease control (graft versus leukemia effect). The only randomized
trial using MUD was a German AML 01/99 trial. Here patients < 60 years of age with high-risk
features (non CBF AML and > 5% blasts on the day 15 bone marrow biopsy) who did not have
a MRD were randomized to a MUD allogeneic versus autologous HCT. The patients who had
a MUD HCT had a superior OS to those treated with an autograft. [36]
Improvements in human leukocyte antigen (HLA) sequencing and selection of donors have
reduced the effect of GVHD in this setting. [40] Better treatment options for the conditioning
regimen and preventing and treating acute GVHD have provided more confidence in the
procedure. [41] Tacrolimus and methotrexate are widely used as GVHD prophylaxis with or
without anti-thymocyte globulin (ATG). Newer GVHD prophylaxis combinations such as si‐
rolimus and tacrolimus [42-44], and ATG-Fresenius have reduced the incidence of both
acute and chronic GVHD without impacting relapse or OS. [45]
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A major challenge which remains is the older patient conventionally described as older than
60 years of age. [46] Interestingly in the case of allogeneic transplantation the threshold for the
older patient is closer to 50 years. These patients are affected by worse prognostic factors,
comorbidities, and intolerance to therapy. [47] However, multiple reports have demonstrated
that transplant is possible with the appropriate conditioning regimen utilizing a non-myeloa‐
blative or reduced intensity dosing of therapy. [48]Although no randomized trial between
conventional therapy and HCT has been reported to date, results suggest that outcomes are
better than conventional chemotherapy for this group of patients. [49, 50] More on this will be
discussed later in this chapter.
3. Chronic myeloid leukemia
Translocation between chromosomes 9 and 22 (t(9;22) or Philadelphia chromosome (Ph+) leads
to an abnormal fusion protein (BCR-ABL) with dysregulated tyrosine kinase activity resulting
in a myeloproliferative disorder characterized by abnormal white cell production known as
chronic myeloid leukemia (CML). Without therapy, CML has a predictable progression from
a chronic phase (CP) to the more advanced accelerated (AP) and/or blast (BP) phases.Since the
introduction of tyrosine kinase inhibitors (TKIs) in October 2001, allogeneic hematopoietic
stem cell transplant (HCT) has shifted from a first-line treatment option and to a second-, third-,
or even a fourth-line option [51, 52]. The number of allogeneic transplantations in the post-TKI
era has significantly decreased in CP CML patients; however, the number of patients trans‐
planted in AP or BP remains the same [53].
Given the excellent results of studies using TKIs as upfront treatment for CP CML, a random‐
ized trial to compare HCT to TKIs has not been performed and has not been justified. The use of
TKIs as standard front-line therapy has been supported by few retrospective and/or genetically
randomized studies [54, 55]. Imatinib mesylate has activity against progenitors and mature
cells but has limited activity against leukemia stem cells [56, 57]. Unfortunately, the majority of
patients achieving remission with imatinib mesylate continue to have molecular evidence of
persistent disease [58]. Even in those patients who are treated for over 4 years with imatinib me‐
sylate and in remission, BCR-ABL + stem cells are still detected in bone marrow [59].
Allogeneic HCT remains a curative approach with long-term molecular remissions, seen only
rarely with TKIs, as the mechanism of the graft versus leukemia effect relies on the presence
of antigens on leukemia stem cells [60]. Current indications of transplant are reserved,
according to the European leukemia net [61], to the following CML subjects:
• At diagnosis for patients presenting in AP or BP
• Imatinib failure (after second-generation TKI pretreatment) progressing to AP or BP
• Patients with TKI resistant mutations such us T315I
• All patients failing second-generation TKI treatment.
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Definitions of imatinib mesylate failure are: 1) a lack to achieve complete hematological
remission at 3 months; 2) failure to achieve any cytogenetic response at 6 months; 3) persistence
of more than 35% Ph+ metaphases at 12 months; or 4) less than complete cytogenetic response
at 18 months. Resistance to imatinib mesylate is defined as loss of complete hematological
response or complete cytogenetic response or development during imatinib mesylate treat‐
ment of an ABL kinase mutation leading to its resistance.
In summary, the present use of allogeneic HCT is reserved for patients with poor response to
TKIs and/or those with advanced disease. Saussele et al. reported an interim analysis from the
German CML Study group IV in patients who underwent a 5-arm randomization where 84
patients underwent allogeneic HCT as second-line therapy after imatinib mesylate failure
[62].The 3-year survival in CP was 91%, with 59% in AP. The majority of patients (88%)
achieved a molecular remission and reported a very low treatment-related mortality (TRM)
(8%).The authors at that time concluded that allogeneic HCT could become the preferred
second-line option after imatinib mesylate failure for suitable patients with a donor.
Because most patients are treated with TKI before transplant, it is important to understand
whether this strategy could potentially jeopardize HCT results. Retrospective comparison of
patients treated with imatinib mesylate pre-HCT compared with historical controls showed
no effect on OS, progression-free survival, and non-relapse mortality [63]. Based on a Center
for International Blood and Marrow Transplant Research (CIBMTR) study reported by Lee et
al., imatinib mesylate before HCT in patients with CP CML leads to a better survival but no
statistically significant difference in TRM, relapse, and leukemia-free survival and no differ‐
ences reported in advanced CML. These results are re-assuring for the majority of patients that
today are treated with TKIs prior to allogeneic HCT [64]. In summary, imatinib mesylate use
before HCT has been shown to not increase toxicity and/or engraftment of subsequent
allogeneic HCT [65-68]. Interestingly, risk of chronic GVHD may be decreased with the use of
imatinib mesylate pre-HCT [67] and may potentially target GVHD-related fibrotic features if
they developed post-HCT[69, 70]. In addition, the use of TKIs before HCT has been shown to
improve outcomes if a patient achieves major cytogenetic remission compared to those who
do not [67].
Imatinib mesylate as frontline for CP patients leads to a major cytogenetic response rate
of 89% and OS of 86% at 7 years. Unfortunately, secondary resistance develops at a rate
of 4% per year for CP [71] and 70-90% in AP/BP phases [72-74].With the development of
second-generation TKIs  (dasatinib  and nilotinib)  and the  compelling results  shown of  a
major  cytogenetic  response of  up to  45% for  imatinib  mesylate  failure  patients  [75,  76],
recommendations  for  HCT are  reserved for  patients  who have  failed  not  only  imatinib
but  also second-generation TKIs[61].  Front-line therapy with second-generation TKIs  for
CP CML it is now warranted [77, 78].
The majority of mutations are susceptible to second-generation TKIs, but some are resistant
not only to first-generation but also to all second-generation TKIs. Threonine-to-isoleucine
substitution at position 315 of Bcr-Abl fusion protein (T315I mutation) is well established to
confer resistance to most TKIs [61]. Multiple reports have shown encouraging results with
allogeneic HCT in patients for whom allogeneic HCT is recommended earlier in the disease
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course [79-82]. The results from efforts to develop third-line TKIs to target resistant mutations
are encouraging. On September 4, 2012, the U.S. Food and Drug Administration approved
bosutinib tablets (Bosulif®, Pfizer, Inc.) for the treatment of CP, AP, and BP Ph+ CML in adult
patients with imatinib-resistant mutants of Abl or intolerance to prior therapy (http://
www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm). The pivotal
PACE trial data have shown robust anti-leukemic activity of ponatinib in patients with CML
at all stages, who are either resistant or intolerant to dasatinib or nilotinib or who have the
T315I mutation [83].
For advanced patients, TKIs have facilitated a bridge to the HCT procedure. Long-term
outcomes with imatinib mesylate for AP CML are only up to 47 months and 7 months for BP
CML[84-86] with a 2-year OS of only 47% and 16% for patients in AP and BP, respectively [87].
The goal for advanced disease patients is to achieve a second CP in order to proceed with
allogeneic HCT. Because the rate of mutations is highly increased for these patients, assessment
of mutation profile is quite vital to guide TKI selection. Allogeneic HCT represents the best
chance for long-term success or even cure in AP/BP CML [88]. Given selection bias, only
unfavorable risk CML patients should proceed to allogeneic HCT these days. Reduced
intensity conditioning (RIC) regimens have facilitated transplant access to more frail popula‐
tions; unfortunately a higher relapse risk remains due to aggressive disease and reduced
chemotherapy [89-92]. Therefore, there is a need for strategies to improve current leukemia-
free survival post-allogeneic HCT.Measurement of minimal residual disease has become
particularly important as it has been shown that patients who have increased BCR-ABL
expression levels (more than 10-4) experience higher relapses rates [93-95]. Serial BCR-ABL RT-
PCR is considered a standard practice and can be used to guide clinical interventions. It is not
unusual to decect low level molecular disease; however treatment should be reserved for those
patients whose markers increase over time or remain persistently positive. Maintenance
therapy with TKIs post-transplant has proven to be tolerable [96]. Carpenter et al. reported
that prophylactic use of imatinib mesylate for 1 year in Ph+ acute lymphoblastic leukemia
(ALL) and CML lead to a low risk of relapse (18%) [97]. Other groups have also shown that
use of TKIs post-HCT can help to minimize relapse risk [98, 99] and/or effectively control
relapse post-HCT [100]. Experience of second-generation TKIs in the post-HCT setting are
currently being explored in clinical trials (http://clinicaltrials.gov/ct2/show/NCT00702403). An
early approach is to consider maintenance with a TKI in those who have shown activity prior
to transplant, and BCR-ABL mutation analysis should guide TKI selection. Role of TKIs in the
post-HCT setting should also be studied in the context of donor lymphocyte infusions (DLI)
as immunotherapy, as it has been shown to be effective for management of early relapse in the
pre-TKI era. The synergistic role of TKI with DLI should be further explored [101].
In conclusion, several effective drugs are available today to treat CML upfront during the
chronic phase of the disease. Careful monitoring for BCR/ABL and mutation analysis are
warranted to determine which patients will be in need of second- or third-line therapies. For
patients with advanced-phase disease, HCT remains the option of choice, using a TKI to bridge
to allogeneic HCT.
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4. Myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a clonal stem cell disorder that results in a heterogeneous
group of disorders characterized by excessive apoptosis of bone marrow cells. It is character‐
ized by low peripheral counts, marrow dysplasia, proliferation and loss of differentiation of
hematopoietic progenitors with a median age of 60-70 years at presentation. Mortality is
related to bone marrow failure and evolution to secondary AML [102]. Despite development
of novel therapeutic agents over the past decades, allogeneic HCT remains the only curative
option in this disease. To date, HCT indications, timing, and incorporation of novel drugs
before and/or after HCT remains a challenge. Additionally, whether novel treatment agents
for elderly MDS patients should be pursued instead of allogeneic HCT remains unanswered.
A recent retrospective cohort analysis suggested a survival advantage for allogeneic HCT
(39%) compared with azacytidine (23%) therapy in medically fit patients with high-risk MDS
of 60-70 years of age [103]. The German MDS study group is testing 5-azacytidine compared
to allogeneic HCT in a prospective study for patients with International Prognostic Scoring
System (IPSS) intermediate II or high-risk up to age 70 years (NCT01404741).
The IPSS system is based on peripheral blood cytopenias, cytogenetics, and marrow myeloblast
percentages and is generally used to identify HCT candidates [104]. A limitation of the IPSS
score is that it does not take into account patient age; therefore, development of other scoring
system has been proposed. The World Health Organization classification and the World
Health Organization classification–based Prognostic Scoring System have both shown relevant
prognostic values in post-HCT MDS outcome for OS and relapse [105, 106]. In a recent analysis
of 1915 patients with MDS, only 26% had primary MDS without prior therapy that could be
classified with the IPSS system. A multivariate analysis of prognostic factors determined worst
outcome for poor performance, older age, thrombocytopenia, anemia, increased bone marrow
blasts, leukocytosis, chromosome 7 or complex (≥3) abnormalities, and prior transfusions. This
new MDS prognostic model divided patients into 4 prognostic groups with significantly
different outcomes with the advantage that it accounts for duration of MDS and prior therapy
and is applicable to any patient with MDS at any time during the course of MDS [107].
A Markov decision analysis model designed by Cutler et al. showed that for low and inter‐
mediate-1 IPSS groups, delayed transplantation maximized OS; for intermediate-2 and high
IPSS groups, HCT at diagnosis maximized OS and was associated with maximal life expect‐
ancy [108]. In contrast, other studies have suggested that younger patients with less advanced
disease have a better transplantation outcome [105, 109]. An evidence-based review consensus
by the American Society of Blood and Marrow Transplantation recommended early HCT for
patients with IPSS intermediate-2 or high-risk at diagnosis and selected patients with lower
risk disease at diagnosis who have poor prognostic features (such as older age, refractory
cytopenias, and/or transfusion dependence) [110]. The American Society of Blood and Marrow
Transplantation recommendations are limited as they are based on studies using IPSS score
instead of more comprehensive ones; in addition, it only applies to newly diagnosed patients
and excludes MDS subjects with treatment-related MDS/t-AML and chronic myelomonocytic
leukemia subtype [111].
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Factors that determine risk of progression from MDS to t-AML and that more accurately
predict disease progression and HCT indication have been studied in the context of MDS
phenotype and/or disease biology. With a patient group of 692 MDS patients, a European
group analyzed outcome and reported worse OS and relapse rates based on poor cytogenetics
[112]. In a multivariate analysis by Chang et al. comparing patients with secondary MDS or
transformed to AML(t-AML) to de novo MDS, no significant differences in outcome were
shown between the 2 cohorts and overall inferior outcome was shown in patients with
secondary MDS/tAML, as the majority of advanced patients has increased frequency of high-
risk cytogenetics [113]. Flow cytometric scoring system is predictive of post-HCT outcomes
even after adjusting for risk factors such as marrow myeloblast percentage and IPSS score
[114]. Cases of MDS classified as AML by microarray-based GEP assays had more aggressive
disease and more rapid progression to AML, whereas MDS cases classified as “none-of-the-
targets” had a more indolent clinical course [115]. Tumor necrosis factor-α polymorphisms
affect HCT outcome in a disease-dependent manner [116]. There are many others risk catego‐
rization factors in MDS like FISH, spectral karyotyping, and mutation or deletion analyses
[117-119], although clinical significance remains controversial [120]. Development of a revised
scoring system is warranted to guide the decision-making process to recommend HCT for such
a diverse and heterogeneous clonal condition.
Clinical evolution of disease such us increased transfusion, recurrent infections or bleeding
may also precipitate the decision to proceed with HCT. Elevated serum ferritin levels, as
reflection of increased body iron storage, have been showed to be associated with decreased
OS and DFS, acute GVHD, and infections with myeloablative HCT [121, 122]. Ferritin levels
should guide the need of chelation therapy prior to HCT and/or may guide conditioning
regimen selection [123]. Co-morbidity as a determinant of HCT outcomes has been elegantly
studied by Sorror et al. [124] and applied in the context of AML-MDS [125]. This group
investigated the role of comorbidities, among other risk factors, in stratifying and comparing
patients conditioned with non-myeloablative or myeloablative regimens. Patients with low
HCT-CI scores and either low or high disease risks had probabilities of OS at 2 years of 70%
and 57% after nonmyeloablative conditioning compared to 78% and 50% after myeloablative
conditioning, respectively. Patients with higher HCT-CI scores ( ≥ 3) and either low or high
disease risks had probabilities of OS of 41% and 29% with nonmyeloablative conditioning
compared with 45% and 24% with myeloablative regimens, respectively. After adjusting for
pretransplantation differences, stratified outcomes were not significantly different among
patients receiving nonmyeloablative compared with myeloablative conditioning, with the
exception of lessened nonrelapse mortality (hazard ratio, 0.50; P =.05) in the highest risk group.
This group concluded that patients with low comorbidity scores could be candidates for
prospective randomized trials comparing nonmyeloablative and myeloablative conditioning
regardless of disease status [125]. An additional scoring system has also emphasized the
negative influence of comorbidities on HCT outcomes [126].
Based on published literature, patients up to 70 years of age can tolerate allogeneic HCT and
age per se should not be a criterion for patient selection and/or intensity of the conditioning
regimen rather than performance status, comorbidity, and disease status [127].Results from a
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European Group for Blood and Marrow Transplantation (EBMT) report suggested that age is
not a contraindication to HCT; the cumulative incidence of non-relapse mortality at 4 years
was 36% in the 50- to 60-year-old patient group and 39% for the group 60 years or older (P =.
39], with OS not differing between the groups (34% versus 27%, P =.2). In a multivariate analysis
for OS, only advanced stage of the disease at time of transplantation (hazard ratio = 1.55] was
associated with inferior survival [128]. Similar results were reported by the CIBMTR; in a
multivariate analysis, they showed that OS was inferior with low performance status, mis‐
matched unrelated donors, and unfavorable cytogenetic, but age had no impact [129].
To facilitate HCT access to the majority of MDS patients, a RIC regimen has been developed.
The rationale for RIC is to promote graft-versus-leukemia effect without excessive toxicity to
minimize TRM. Many RIC regimens have been developed using combinations of busulfan
with cyclophosphamide or fludarabine, fludarabine with cyclophosphamide, or low-dose total
body irradiation (TBI) (200cG) among others versus the more intense or conventional regimens
based on TBI or busulfan/cyclophosphomide-based regimens. Unfortunately, due to the lack
randomized prospective trials, it remains unknown which conditioning regimen should be
chosen and how “intense and/or reduced” the conditioning should be. In general, the highest
tolerable regimen should be chosen since reduced intensity is associated with a higher relapse
rate, as suggested in multiple retrospective studies [130-136]. RIC HCT with fludarabine/
melphalan and tacrolimus/sirolimus-based GVHD prophylaxis resulted in a relapse incidence
of 20.9% with low-grade acute GVHD [137]. An ongoing prospective randomized trial
comparing RIC versus myeloablative conditioning has been developed to address selection
bias for allogeneic HCT by the EBMT group (NCT00682396).
Disease relapse post-HCT remains a critical issue as long-term outcome is compromised.
Approaches to tackle this issue include pre-HCT induction chemotherapy and/or novel agents
for high-risk patients or drug maintenance to prevent relapse pre-emptively post-HCT, as
opposed to strategies for relapse treatment. Still debatable to date is whether pre-HCT
induction chemotherapy has a role to minimize relapse post-HCT for patients with advanced
MDS. Unfortunately, this remains unanswered due to lack of randomized and/or definitive
data [138-141]. Introduction of novel agents in the pre-HCT setting seems feasible, associated
with less toxicity, and may allow for similar post-HCT outcomes when compared to chemo‐
therapy [142].Another approach is to use low-dose 5-azacytidine as maintenance post-HCT.
De Lima et al. determined that the optimal combination was 32 mg/m2 given for at least 4
cycles, with reversible thrombocytopenia as the dose-limiting toxicity. The authors suggested
that this treatment prolonged event-free survival (EFS) and OS [143]. In the event of disease
relapse post-HCT, azacytidine administration is feasible and may induce durable remissions
[144]. DLIs can result in complete remission in some patients, but long-term survival is
infrequent [145]. The Azarela trial, a prospective multicenter phase II trial, was developed to
test whether a combination of 5-azacytidine and DLI would benefit patients with relapsed
MDS post-HCT. Overall response rate was 64% with 20% achieving and staying in CR, 12%
achieved partial response, and 32% showed stable disease with low incidence of acute GVHD
occurring (24%). These data suggest that salvage therapy with combination azacytidine + DLI
is feasible and has significant anti-leukemic activity in relapsed MDS post-HCT [146].
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In conclusion, several factors influence HCT indication and timing for MDS patients. Incor‐
poration of evolving prognostic indicators might help to develop treatment algorithms to
decide the appropriate timing for allogeneic HCT. The ultimate objective is to proceed with
HCT when non-transplantation approaches would result in outcomes lower than those that
would result with allogeneic HCT. Currently, novel HCT approaches are allowing the
consideration of older patients and/or the use of alternative donors to treat MDS. A remaining
question is how to incorporate HCT for those patients that are achieving a CR with hypome‐
thylating agents and/or other novel agents. Development of prospective clinical trial may help
to elucidate these questions within a fast evolving field.
5. Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a bone marrow clonal disease characterized by the
rapid proliferation of immature lymphoblasts. Despite initial control of the disease, the
majority of adult patients will relapse with poor long-term outcomes. Allogeneic HCT has been
used as a salvage therapy for both relapsed patient and high-risk patients with ALL early in
the disease process. The availability of unrelated donors and/or alternative stem cell sources
and the development of RIC transplants have resulted in far more allogeneic transplants being
performed for this rare disease. For adults with ALL, indication and timing of allogeneic HCT
remains debatable as defining the optimal role for allogeneic HCT has been limited by the lack
of prospective data that can only be gained by large multicenter-national trials.
Historically, allogeneic HCT was reserved for high-risk patients, especially for those with Ph
+ ALL. Patients with high-risk features benefit from upfront HCT, including those with
increased white blood count at presentation (>25,000/µL), chromosomal translocations [t(9;22),
t(4;11), t(8;14)], older age (≥30 years), extra-medullary disease at diagnosis, and/or requiring
more than 4 weeks to achieve CR [147]. Strategy to take ALL patients in CR1 for t(9;22) and
t(1;19) have been supported by a trial by the French Group of Therapy for adult ALL (LALA-94)
in a subgroup analysis [148]. Improvement in detection of minimal residual disease has also
helped to assess disease risk, as 10% of patients with a rapid MRD decline to lower than 10(-4)
or below detection limits at day 11 and day 24 were classified as low risk as their 3-year relapse
rate was 0% [149]. Testing MRD with flow cytometry and/or molecular analysis for gene
rearrangements may help to guide transplant decisions.
The largest prospective study of HCT in adult ALL was conducted by the Medical Research
Council in Great Britain (UKALL XII) and the Eastern Cooperative Oncology Group in the
United States (ECOG 2993). In this trial, allogeneic HCT resulted in improved disease control
in all adult patients with ALL, with younger patients with low-risk disease benefiting the most
with allogeneic HCT [150]. This international collaboration prospectively evaluated the role
of allogeneic HCT for adults with ALL and compared autologous HCT with standard chemo‐
therapy. Patients received 2 phases of induction and, if in remission, were assigned to
allogeneic HCT if they had a compatible sibling donor. Patients without a donor were
randomized to chemotherapy for 2.5 years versus an autologous HCT. A donor versus no-
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donor analysis showed that Ph- ALL patients (standard risk) with a donor had a 5-year
improved OS of 53% versus 45% for no donor (P =.01). The relapse rate was significantly lower
(P ≤.001) with HCT in the standard-risk ALL patients. The survival difference was significant
only in standard-risk patients, but not in high-risk patients, who had an impressive reduction
in relapse rate but increased non-relapse mortality that abrogated the OS benefit of allogeneic
HCT. For the no donor group, patients randomized to chemotherapy had a higher 5-year OS
(46%) than those randomized to autologous transplantation (37%; P =.03). In conclusion, MRD
allogeneic HCT for ALL in CR1 provide the most potent anti-leukemic therapy and consider‐
able survival benefit for standard-risk patients. We may also conclude that there is no role for
a single autologous HCT to replace consolidation/maintenance in any risk group.
For high-risk patients, results are conflicting with a recent large meta-analysis from seven
studies of adult high-risk ALL (n=1274) using natural randomization based on donor availa‐
bility combined with intent-to-treat analyses. This study demonstrated that patients in the
donor groups had significantly better survival than patients in the no-donor groups (hazard
ratio, 1.29; 95% confidence interval [95% CI], 1.02-1.63 [P =.037]). When only high-risk patients
were included in the analysis, the superiority of the survival advantage was even greater
(hazard ratio, 1.42; 95% CI, 1.06-1.90 [P =.019]) [151]. In addition, a recent systematic review
and meta-analysis supported MRD HCT as the optimal post-remission therapy in ALL patients
aged 15 years or over, resulting in improved OS and DFS with a significant reduction of disease
relapse but with increased non-relapse mortality[152]. Interpretation of the results of the
multicenter international trial has led to advocating early allogeneic HCT for patients with
standard risk for some transplantation teams while others have preferred a more personalized
approach as reports from various study groups differ and are often contradictory, leading to
difficulty in interpreting the data [153, 154].
Historically, allogeneic HCT has been the standard of care for patients with high-risk Ph+ ALL
in CR1. With the introduction of TKIs over the past decade, a treatment algorithm introducing
TKIs in combination with allogeneic HCT for adult patients with Ph+ ALL is mandated. TKIs
have been used in the upfront induction/maintenance chemotherapy setting and as mainte‐
nance post-HCT to prevent disease relapse in Ph+ ALL patients. Whether use of TKIs has an
impact on OS when combined with HCT or whether TKIs will replace the use of allogeneic
HCT remains unanswered to date. Multiple studies have shown the advantage of using
imatinib mesylate in the induction/consolidation phase, allowing better remission rates and
durable response with minimal toxicity as well as facilitating access and planning for an
allogeneic HCT [154-159]. Review of these trials has suggested that over 90% of patients
achieved a complete response as previously reviewed [154, 160]. Dasatinib, a multi-target
kinase inhibitor of BCR-ABL and SRC family kinases, has been shown to induce responses in
patients with imatinib-resistant or intolerant Ph+ ALL. In the START-L trial, major hematologic
responses were achieved in 42%(15/36) of patients, 67% of whom remained progression-free
when used at a dose of 140 mg. Complete cytogenetic responses were attained by 58% (21/36)
of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not
preclude a response to dasatinib in this trial [161], suggesting a role for dasatinib to manage
Ph+ ALL upfront [161]. Ravandi et al. examined the efficacy and safety of combining chemo‐
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therapy with dasatinib in patients with Ph+ ALL and determined that 94% achieved CR with
an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is
effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL[162].
Nilotinib has also been tested for the management of relapsed/refractory Ph+ ALL with
encouraging results[163].
TKI treatment is  also a promising strategy when used as a consolidation strategy to in‐
duce and/or maintain molecular responses to decrease relapse rate after allogeneic HCT.
Carpenter el al. reported safety data in 15 patients with Ph+ ALL who were enrolled in a
prospective  study and given imatinib  from the  time of  engraftment  until  day  265  after
HCT [97].  A clinical trial is currently ongoing to determine the safety of the administra‐
tion of  nilotinib between day 81 and day 365 after  HCT in patients  with Ph+ leukemia
(http://clinicaltrials.gov/show/NCT00702403).  Lastly,  TKIs  have  been  shown  to  be  effec‐
tive for management of relapse in Ph+ ALL in the post-HCT setting, although these data
are based on few reports [160].  In summary, TKIs should be incorporated as a pre-HCT
strategy to facilitate higher response rate and to improve both quality and durability of
responses  prior  to  allografting.  TKIs  are  also  a  reasonable  and promising strategy after
allogeneic HCT to consolidate and maintain molecular responses that may ultimately im‐
prove  survival  for  patients  with  Ph+  ALL.  The  optimal  duration  of  therapy  post-HCT,
particularly  in  patients  with  sustained  molecular  response,  remains  to  be  determined.
Whether TKI incorporation in the treatment strategy would impact OS is still unclear. In
the  absence  of  large  prospective  randomized  trials  comparing  imatinib-chemotherapy
regimens  versus  allo-HCT as  a  consolidative  strategy,  allo-HCT remains  the  best  thera‐
peutic approach that offers a possibility of cure in Ph+ ALL [160].
There  is  increased interest  in  developing strategies  to  minimize toxicity  associated with
allogeneic HCT, especially after the results of the UK ALL XII ECOG 2993 study, which
showed a significant  TRM in patients  over the age of  35 years despite  better  control  of
disease  [150].  Several  groups  have  sought  to  minimize  morbidity  and  mortality  in  this
group of  patents  through reduced intensity  approaches,  allowing for  access  to  HCT for
majority  of  Ph+  ALL  subjects  [164].  Unfortunately,  there  is  no  prospective  trials  using
RIC  for  this  disease  published  in  the  literature.  Few  recent  retrospective  series  have
been  reported  with  2-year  OS  and  DFS  between  50  and  61.5%  [165].  We  previously
published our initial experience with FLU and BU in adult ALL patients, which showed
a 2-year  cumulative  incidence  of  relapse  of  19% (95% CI  8%-41%)  for  those  transplant‐
ed in  CR1 and 48% (29%-80%) in  those with more advanced disease,  with a  2-year  OS
of  54% (95% CI 39%-69%).  Relapse-free  survival  at  2  years  was 63% (95% CI 45%-81%)
for  patients  transplanted  in  CR1  and  34%  (95%  CI  11%-57%)  for  patients  transplanted
in  more  advanced disease.  We concluded that,  compared to  irradiation-containing  regi‐
mens,  FLU and PK-targeted BU appear safer  and similarly effective in controlling ALL,
providing a  treatment  option for  adult  patients  with ALL [166].  Nonmyeloablative allo‐
geneic  HCT  approach  is  promising  but  its  role  for  management  of  Ph+  ALL  requires
further investigations [154].
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6. Lymphoma
Both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent a large group
of diverse diseases. They are characterized by enlarged lymph nodes, splenomegaly, and
constitutional symptoms. These disorders can present with bone marrow and extramedullary
consequences. As a whole, they respond to combination chemotherapy. For patients who have
relapsed or are refractory to initial therapy autologous HCT is the treatment of choice. The
Parma group study, established the superiority of high-dose chemotherapy and autologous
HCT over conventional salvage chemotherapy in a randomized multi-center trial for relapsed
aggressive NHL [167]. Based on this study, autologous HCT became the standard of care for
chemotherapy-sensitive relapsed or primary refractory aggressive NHL. There are instances
where allogeneic HCT is the preferred approach for lymphoma.
6.1. Non-hodgkin lymphoma
6.1.1. Diffuse large B cell lymphoma (DLBCL)
The number of published studies using allogeneic HCT in DLBCL are limited and do not allow
definitive conclusions. Allogeneic HCT has generally been used as treatment for patients who
have relapsed after autologous HCT and on occasion for relapsed high-risk or refractory
disease. No prospective comparative studies are available in this setting. A retrospective study
by the CIBMTR compared the outcomes of DLBCL patients undergoing first autologous HCT
(n = 837) or HLA-identical MSD allogeneic HCT with myeloablative conditioning (n =79).
Allogeneic HCT was associated with higher TRM but with a similar risk of disease progression
compared with lower-risk patients who received autologus HCT. [168] The European Group
for Blood and Marrow Transplantation (EBMT) registry published a retrospective analysis of
101 patients. Approximately two-thirds of the patients received a reduced-intensity condi‐
tioning (RIC) regimen and 70% had an MSD. Non relapse mortality (NRM) was low with a
rate of 28.2%, a relapse rate of 30% and an OS rate of 53%. Patients with a long remission after
autologous HCT and with sensitive disease at allogeneic HCT appear to be the best candidates
for this approach. [169] Thus, the use of allogeneic transplantation should be reserved for
relapsed and refractory DLBCL that is responsive to the last line of therapy.
6.2. Follicular lymphoma (FL)
FL comprises approximately 25% of all newly diagnosed NHL cases. As an indolent lympho‐
ma, the disease course is one of remissions and relapses with chemotherapy, followed
inevitably by resistance and transformation to a more aggressive NHL histology. Trials from
the several European Groups compared consolidative autologous HCT to chemotherapy ±
interferon alfa (IFN-α) maintenance therapy or rituximab. [170-173] As autologous HCT
provides no benefit in OS in FL it is currently not recommended as consolidation therapy.
The graft-vs-lymphoma effect afforded by allogeneic HCT is appealing as a potential curative
approach in FL. Myeloablative conditioning allogeneic HCT, due to high TRM has not resulted
in an improved OS in this disease. [174, 175] RIC allogeneic HCT is associated with a lower
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TRM and the graft-vs-lymphoma effect may be beneficial in this indolent disease. Several
studies have been published using this approach. The MD Anderson BMT program published
results of their single institution trial of 43 patients with relapsed/refractory FL receiving a RIC
allogeneic HCT with high doses of rituximab during and after conditioning. The PFS and OS
rates were robust at 83% and 85%, respectively. [176] Currently, the BMT-CTN (0701) is
confirming these results in a multi-institution trial.
6.3. Mantle cell lymphoma (MCL)
MCL is an aggressive NHL that often is responsive to initial chemotherapy but has a very high
relapse rate and is incurable with conventional chemotherapy. With intensified induction
regimens and the addition of rituximab, a higher proportion of patients achieve complete
remission; however, long term cures are rare. [177] Autologous HCT provides very good
control of the disease particularly in patients who received transplants in CR1. [178, 179] The
Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted good outcomes for
patients in the good- and intermediate-risk. Unfortunately the poor-risk group had a disap‐
pointing survival, suggesting that these patients may be better suited for allogeneic HCT. [180]
To reduce toxicity and mortality in these heavily pretreated and older patients, RIC allogeneic
HCT has been proposed with promising results. Treatment with a nonmyeloablative condi‐
tioning regimen and allogeneic HCT in 33 patients with relapsed and refractory MCL resulted
in an OS rate of 65%. None of the patients transplanted in CR had relapsed after a median
follow-up of 2 years. [181] Long term follow upof RIC allogeneic HCT in 35 patients with
relapsed or refractory MCL demonstrated a low TRM rate and outcomes in which median OS
had not been reached. [182] Finally, The British Society for Blood and Marrow Transplantation
published the results of a retrospective analysis of 70 heavily pretreated patients with relapsed/
refractory MCL who received RIC allogeneic HCT with or without alemtuzumab with or
without DLI to boost the graft vs-lymphoma effect. The 3-year OS rate for patients who
received donor lymphocyte infusions for relapse was 79%. [183] All of these studies demon‐
strated a plateau on the survival curves. Based on these reports, allogeneic HCT appears to be
effective therapy for relapsed and refractory MCL and the only one associated with long-term
remission. It will be necessary to complete a prospective, randomized study to define the role
of upfront allogeneic HCT in MCL patients.
6.4. T-cell lymphoma
T-cell NHL (Peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell
lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)) are a heterogeneous group
of lymphomas which for the most part have an inferior prognosis when compared to B-cell
NHL after CHOP therapy. With the exception of anaplastic large-cell kinase-positive (ALK)
positive anaplastic large-cell lymphoma, T-cell NHL Carries a poor prognosis with low DFS
and OS with standard chemotherapy. Several studies have demonstrated the use of autologous
HCT in T-cell lymphoma has similar results to DLBCL. [184-189].
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Allogeneic HCT has been proposed for the treatment of T-cell Lymphoma because of the
potential graft-vs-lymphoma effect. There are limited studies in this field but the results have
been promising. A retrospective analysis from France on 77 patients who underwent allogeneic
HCT for PTCL resulted in a 5-year OS rates of 57%. Myeloablative conditioning was used in
the majority of the patients. Patients with AITL had the best outcome, with a 5-year OS rate of
80%. Risk of relapse was low; however, the high TRM limited the benefit of the myeloablative
approach. [190] RIC allogeneic HCT was published a prospective phase II trial using a reduced
intensity regimen in 17 patients with PTCL. As expected TRM was low and the estimated 3-
year OS was 81%. [191] In summary, the use of RIC allogeneic HCT through a lower TRM and
allows transplant in older and heavily pretreated patients with reasonable OS. Certain T-cell
entities such as hepatosplenic T-cell lymphoma, adult T-cell leukemia/ lymphoma, and
systemic extranodal NK/T-cell lymphoma carry such a poor prognosis that allogeneic HCT is
justified as part of the initial treatment. The use of prognostic indexes such help identify
patients with extremely high risk of relapse who may also benefit from an allograft. Only
prospective multicenter trials will define the role of allogeneic HCT in these aggressive
lymphomas.
6.5. Hodgkin lymphoma
Combination chemotherapy with or without radiation therapy results in long-term DFS and
OS for about 80% of newly diagnosed patients with HL. [192] As in NHL autologous HCT is
well established for the treatment of disease. [193] An approach to minimize relapse after
autologous HCT for high-risk patients using the anti-CD30 antibody (brentuximab) conjugat‐
ed to an anti-tubulin drug (vedotin) [SGN-35][194] is currently being studied in a randomized
phase III placebo-controlled trial as maintenance therapy following autologous HCT.
Because of prior intensive therapy, RIC allogeneic HCT is an appropriate option in candidates
for patients with HL. [195-198] Recent retrospective analyses demonstrate improved PFS and
OS compared to additional salvage therapy for patients treated with this approach after relapse
following autologous HCT. [197, 199] More importantly, outcomes with MRD vs MUD do not
appear to be different. [196, 198]
7. Conditioning regimens
7.1. Myeloablative conditioning
Allogeneic bone marrow transplantation is the most intensive post-remission therapy used for
management of malignant disorders over the past decades. Toxicity of a conditioning regimen
can impact on overall morbidity, including interstitial pneumonitis, sinusoidal obstruction
syndrome/veno-occlusive disease, and may lead to an increased incidence of GVHD. Despite
current understanding of the transplantation process, the optimal chemotherapy and/or
radiation conditioning regimen remains unknown. Few data from comparative or randomized
studies are available to address this issue. Allogeneic hematopoietic cells serve a dual purpose,
not only to restore hematopoiesis but also to impose immunologic effects against malignant
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clones, a process known as graft versus leukemia. This has led to the development of a
conditioning regimen that will minimize toxicity with preservation of graft versus leukemia
effect as the main mechanism of action to eradicate disease.
The spectrum of conditioning intensity has been defined in three categories: 1) myeloablative,
which causes irreversible marrow aplasia if transplantation is not performed; 2) nonmyeloa‐
blative, which cause minimal marrow suppression; and 3) RIC, which causes cytopenias of
intermediate duration [200]. Assignment to these categories is based on the duration of
cytopenia and on the requirement for stem cell support. Myeloablative regimens cause
irreversible cytopenia, and stem cell support is mandatory. Nonmyeloablative regimens cause
minimal cytopenia and can be given also without stem cell support. RIC causes cytopenias of
variable duration and should be given with stem cell support, although cytopenia may not be
irreversible. Compared with high-dose MA preparative regimens, NMA or RIC regimens are
associated with shorter inpatient hospital stays, reduced need for transfusions [201], and a
shorter duration of neutropenia with fewer bacterial infections [202-204]. There is current trend
to adopt less-toxic conditioning regimens to allow access for patients to undergo HCT who
has been previously been excluded because of age or comorbidities. Standardized classification
of conditioning regimen intensities will allow comparisons across studies and interpretation
of study results [200].
Myeloablative regimens, a combination of agents expected to produce profound pancytopenia
and myeloablation within 1-3 weeks from administration, have caused pancytopenia that is
long lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored
by hemopoietic stem cell infusion [200]. Early use of this approached invested on the theory
of dose intensity to eradicate disease. [205]. The two most commonly used myeloablative
conditioning regimens for allografts for leukemia/lymphoma use a combination of high-dose
busulfan combined with cyclophosphamide and cyclophosphamide in combination with TBI.
The Cyclophosphamide-TBI regimen uses a cyclophosphamide dose of 120 mg/kg and 10–15
Gy TBI [23] and busulfan-cyclophosphamide uses a busulfan dose of 16 mg/kg orally and Cy
120 mg/kg [206]. From the available data, there are no significant differences in survival with
these two regimens. There is also no evidence that intensified conditioning improves survival,
as a higher dose of TBI is associated with increased toxicity [205]. Cyclophosphamide or TBI
has also been tested in addition to other chemotherapy agents like melphalan, thiotepa,
etoposide, and dimethylbusulfan. The problem with myeloablative conditioning is the high
TRM that ultimately jeopardizes overall success. The risk of TRM after a myeloablative
regimen has decreased over time, attributed to improved HLA-typing and better supportive
care [207]. Neither regimen explored in the myeloablative setting is suitable for all the
situations and a particular regimen should be selected depending on the clinical situations if
myeloablative approaches are still an option nowadays [208] with the introduction of less toxic
transplantation approaches.
Several  attempts  have been made in the past  30 years  to  limit  early transplant  toxicity,
by  reducing  the  intensity  of  the  conditioning  regimen  as  previously  reviewed  [200].
Within  the  past  20  years,  the  introduction  of  fludarabine  (Flu)  [209,  210]  and  further
dose  reductions  of  alkylating  agents  [211,  212]  or  TBI  has  led  to  minimized  toxicity.
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These regimens were  designed to  allow access  to  HCT for  older  patients  or  because  of
comorbidities  that  would  preclude  HCT.  Enthusiasm  in  the  transplant  community  has
led to adoption of these reduced toxicity modalities [213].  A workshop convened by the
CIBMTR addressed the dose spectrum, which defines a RIC regimen [214]. A total of 56
participants were surveyed, and 67% agreed that a RIC regimen should cause reversible
myelosuppression when administered without stem cell support, result in low nonhema‐
tologic  toxicity,  and,  after  transplantation,  result  in  mixed donor–recipient  chimerism at
the  time  of  first  assessment  in  most  patients.  Likewise,  the  majority  (71%)  agreed  or
strongly agreed that regimens including <500 cGy of TBI as a single fraction or 800 cGy
in fractionated doses, busulfan dose <9 mg/kg, melphalan dose <140 mg/m2, and thiotepa
dose  <  10  mg/kg  should  be  considered  RIC  regimens.  However,  only  32%  agreed  or
strongly  agreed that  the  combination of  carmustine,  etoposide,  cytarabine,  and melpha‐
lan  (BEAM)  should  be  considered  a  RIC  regimen.  These  results  demonstrate  that,  al‐
though  HCT  professionals  have  not  reached  a  consensus  on  what  constitutes  a  RIC
regimen, most accept currently used criteria and operational definitions [214].
RIC is an intermediate category of regimens that causes pancytopenia and requires stem cell
support if prolonged and autologous recovery is possible. An improved rate of toxicity is
achieved by reducing the dose of alkylating agents or TBI by at least 30%. Most often, these
regimens combine Flu with an alkylating agent, melphalan [215],Bu [211],thiotepa[212] in
reduced doses, or Flu with reduced-dose TBI [216]. Decreased TRM has been successfully
achieved with this approach [217, 218] Among the published phase II trials, leukemia relapse
remained consistently the main cause of treatment failure after RIC or nonmyeloablative
conditioning, with 2- to 4-year relapse rates ranging from 30% to 61%. Mohty et al.recently
updated results of the first prospective trial directly comparing RIC allogeneic HCT versus
consolidation chemotherapy in patients with AML using “genetic allocation.” In an intent-to-
treat analysis, leukemia-free survival was superior in the donor group (60% versus 23% at 7
years; P =.003) but with a significant relapse risk [219]. Recent retrospective analysis demon‐
strated that RIC has similar outcomes to MAC in patients with AML or MDS. [217, 220] Because
of prior therapy and older age, as described above in the Lymphoma section RIC allogeneic
HCT is appropriate for most those patients. Allogeneic transplantation has evolved signifi‐
cantly in the last 40 plus years of use as stem cell therapy. To further improve its outcomes
patients should be selected early and the appropriate regimen should be used to optimize the
anti-malignancy effect.
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